Blastic plasmacytoid dendritic cell neoplasm without cutaneous manifestation: A case report

Daliparty, Vasudev Malik; Garala, Pavan; Razzeto, Mariano; Rehman, Faseeha; Razzeto, Alejandra; Amoozgar, Behzad

dc.contributor.author	Razzeto, Alejandra
dc.contributor.author	Garala, Pavan
dc.contributor.author	Amoozgar, Behzad
dc.contributor.author	Daliparty, Vasudev Malik
dc.contributor.author	Rehman, Faseeha
dc.contributor.author	Razzeto, Mariano
dc.date.accessioned	2022-02-01T21:18:27Z
dc.date.available	2022-02-01T21:18:27Z
dc.date.issued	2021
dc.identifier.uri	https://hdl.handle.net/20.500.12866/11297
dc.description.abstract	Background: As an uncommon malignancy with the highest prevalence in the elderly population, blastic plasmacytoid dendritic cell neoplasm or BPDCN is a hematologic disorder with unknown pathogenesis and devastating out-comes. This neoplasm usually manifests in the skin but can also involve the bone marrow, and less frequently the central nervous system (CNS). However, it does not exclude other organs and can even be associated with other malignancies. Here, we discuss an interesting case of BPDCN in an 85-year-old man who mainly presented with dizziness and weakness. Physical examination revealed splenomegaly, laboratory tests showed pancytopenia, and peripheral blood smear depicted metamyelocytes. Further workup including bone marrow biopsy revealed atypical cells and flow cytometry disclosed 84% blasts positive for cluster of differentiation (CD) 4, CD53, and CD156 suggestive of BPDCN. Moreover, cerebrospinal fluid (CSF) studies came back positive for tumor plasmacytoid dendritic cells. The patient underwent chemotherapy with CHOP, mini-CHOP regimens, and venetoclax, as well as treatment for CNS involvement. He achieved remission, but unfortunately had a recurrence of the disease. Later he was admitted due to pneumonia with concomitant recurrent pulmonary effusions complicated by multior-gan dysfunction and subsequently died. The diagnosis of BPDCN can be very challenging, and high clinical suspicion and intuition are required to reach the diagnosis, especially when patients do not present with cutaneous involvement. Concerning treatment op-tions, novel therapies such as tagraxofusp, a CD123-directed cytotoxin, are emerging in the hope of decreas-ing the rate of mortality for this aggressive malignancy	en_US
dc.language.iso	eng
dc.publisher	International Scientific Literature
dc.relation.ispartofseries	American Journal of Case Reports
dc.rights	info:eu-repo/semantics/restrictedAccess
dc.subject	aged	en_US
dc.subject	Aged	en_US
dc.subject	human	en_US
dc.subject	Humans	en_US
dc.subject	male	en_US
dc.subject	Male	en_US
dc.subject	Aged, 80 and over	en_US
dc.subject	very elderly	en_US
dc.subject	complication	en_US
dc.subject	case report	en_US
dc.subject	skin	en_US
dc.subject	Skin	en_US
dc.subject	Neoplasm Recurrence, Local	en_US
dc.subject	tumor recurrence	en_US
dc.subject	Bone Marrow Neoplasms	en_US
dc.subject	dendritic cell	en_US
dc.subject	Dendritic Cells	en_US
dc.subject	hematologic disease	en_US
dc.subject	Hematologic Neoplasms	en_US
dc.subject	Leukemia	en_US
dc.subject	Rare Diseases	en_US
dc.subject	Skin Neoplasms	en_US
dc.subject	skin tumor	en_US
dc.title	Blastic plasmacytoid dendritic cell neoplasm without cutaneous manifestation: A case report	en_US
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	https://doi.org/10.12659/AJCR.932887
dc.subject.ocde	https://purl.org/pe-repo/ocde/ford#3.02.15
dc.relation.issn	1941-5923